 Protein Kinase Inhibitors
"Protein Kinase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that inhibit PROTEIN KINASES.
| Descriptor ID |
D047428
|
| MeSH Number(s) |
D27.505.519.389.755
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Protein Kinase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Protein Kinase Inhibitors".
This graph shows the total number of publications written about "Protein Kinase Inhibitors" by people in this website by year, and whether "Protein Kinase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 | | 1998 | 0 | 2 | 2 | | 2007 | 2 | 0 | 2 | | 2008 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 0 | 1 | | 2012 | 0 | 3 | 3 | | 2013 | 1 | 2 | 3 | | 2014 | 2 | 0 | 2 | | 2015 | 1 | 1 | 2 | | 2017 | 1 | 4 | 5 | | 2018 | 0 | 2 | 2 | | 2019 | 4 | 0 | 4 | | 2020 | 1 | 4 | 5 | | 2023 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Protein Kinase Inhibitors" by people in Profiles.
-
John T, Groh? C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong V, Melotti B, Fidler MJ, Chen J, Albayaty M, Stachowiak M, Taggart S, Wu YL, Tsuboi M, Herbst RS, Majem M. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial. J Thorac Oncol. 2023 09; 18(9):1209-1221.
-
Gordon LI, Karmali R, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau FI, Radford J, de Oteyza JP, Zinzani PL, Iyer SP, Townsend W, Miao H, Proscurshim I, Wang S, Katyayan S, Yuan Y, Zhu J, Stumpo K, Shou Y, Carpio C, Bosch F. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma: updated data with mivavotinib (TAK-659/CB-659). Oncotarget. 2023 01 26; 14:57-70.
-
Jelinek MJ, Aggarwal C. Adjuvant Osimertinib: A New Standard of Care. Oncologist. 2021 04; 26(4):263-265.
-
Pulido I, Ollosi S, Aparisi S, Becker JH, Aliena-Valero A, Benet M, Rodr?guez ML, L?pez A, Tamayo-Torres E, Chuli?-Peris L, Garc?a-Ca?averas JC, Soucheray M, Dalheim AV, Salom JB, Qiu W, Kaja S, Fern?ndez-Coronado JA, Alandes S, Alc?cer J, Al-Shahrour F, Borgia JA, Juan O, Nishimura MI, Lahoz A, Carretero J, Shimamura T. Endothelin-1-Mediated Drug Resistance in EGFR-Mutant Non-Small Cell Lung Carcinoma. Cancer Res. 2020 10 01; 80(19):4224-4232.
-
Leal TA, Argento AC, Bhadra K, Hogarth DK, Grigorieva J, Hartfield RM, McDonald RC, Bonomi PD. Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis. Curr Med Res Opin. 2020 09; 36(9):1497-1505.
-
Gordon LI, Kaplan JB, Popat R, Burris HA, Ferrari S, Madan S, Patel MR, Gritti G, El-Sharkawi D, Chau I, Radford JA, P?rez de Oteyza J, Zinzani PL, Iyer S, Townsend W, Karmali R, Miao H, Proscurshim I, Wang S, Wu Y, Stumpo K, Shou Y, Carpio C, Bosch F. Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. Clin Cancer Res. 2020 07 15; 26(14):3546-3556.
-
Schmidt S, Liu Y, Hu ZH, Williams KM, Lazarus HM, Vij R, Kharfan-Dabaja MA, Ort? G, Wiernik PH, Weisdorf D, Kamble RT, Herzig R, Wirk B, Cerny J, Bacher U, Chaudhri NA, Nathan S, Farhadfar N, Aljurf M, Gergis U, Szer J, Seo S, Hsu JW, Olsson RF, Maharaj D, George B, Hildebrandt GC, Agrawal V, Nishihori T, Abdel-Azim H, Alyea E, Popat U, Sobecks R, Scott BL, Holter Chakrabarty J, Saber W. The Role of Donor Lymphocyte Infusion (DLI) in Post-Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era. Biol Blood Marrow Transplant. 2020 06; 26(6):1137-1143.
-
Jelinek MJ, Vokes EE. Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains? J Clin Oncol. 2019 11 01; 37(31):2807-2814.
-
Jelinek MJ, Armstrong SA, Patel JD, Subramaniam DS. Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy. Clin Lung Cancer. 2019 11; 20(6):e597-e600.
-
Becker JH, Gao Y, Soucheray M, Pulido I, Kikuchi E, Rodr?guez ML, Gandhi R, Lafuente-Sanchis A, Aup? M, Alc?cer Fern?ndez-Coronado J, Mart?n-Martorell P, Cremades A, Galbis-Caravajal JM, Alc?cer J, Christensen CL, Simms P, Hess A, Asahina H, Kahle MP, Al-Shahrour F, Borgia JA, Lahoz A, Insa A, Juan O, J?nne PA, Wong KK, Carretero J, Shimamura T. CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC. Cancer Res. 2019 09 01; 79(17):4439-4452.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|